ORIGINAL_ARTICLE
Assessment of weight, Body Mass Index and Waist circumference in obese and overweight patients following supplementation with Chromium Picolinate
Background and Purpose: Obesity is a major health problem and its prevalence in the world is increasing. Based on studies the diseases caused by adipocytokine production and secretion from adipose tissue are associated with obesity. Some studies have showns the speed up in fat loss due to the effects of chromium supplementation on insulin regulation. Therefore this study investigated effects of chromium picolinate supplementation combined with 30 minutes of aerobic exercise on weight, body mass index (BMI), waist circumference of overweight and obese individuals.Methods: This clinical trial involved 100 volunteers,20-50 years old with a body mass index above 25 kg/m2; Participants were randomly divided into two groups: intervention and non-intervention. The intervention group received gμ200 of chromium picolinate daily and 30 minutes of aerobic exercise for 3 months but non-intervention group had only 30 minutes of aerobic exercise. Height, weight and waist circumference were measured before and after intervention.Results: Weight, BMI and waist circumference were reduced in both groups significantly. But the changes in weight (p˂0.001), BMI (p˂0.001) and waist circumference (p˂0.001) in intervention group were significantly more than non-intervention group.Conclusions: In the present study it was shown that chromium picolinate supplementation
combined with 30 minutes of aerobic exercise decreases weight, BMI and waist circumference in overweight and obesity significantly.
https://mjms.mums.ac.ir/article_4516_93972e2951b710416a2414395a04c4ad.pdf
2015-05-22
117
122
10.22038/mjms.2015.4516
Peyvand
Robati
peyvand.robati@gmail.com
1
Master (Msc) at Nutrition Shahid Sadoughi University of Medical Sciences and Health Services
AUTHOR
Hassan
Mozaffari khosravi
mozaffari.kh@gmail.com
2
Professor, Department of Nutrition, Shahid Sadoughi University of Medical Sciences and Health Services
LEAD_AUTHOR
Azadeh
Najarzadeh
azmm1383@yahoo.com
3
Assistant Professor, Department of Nutrition, Shahid Sadoughi University of Medical Sciences and Health Services
AUTHOR
Ali
Dehghani
4
Professor of Biostatistics, Department of Epidemiology, Shahid Sadoughi University of Medical Sciences and Health Services
AUTHOR
Elnaz
Khorrami
e_khorami22@yahoo.com
5
Master (Msc) at Nutrition School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences
AUTHOR
1. Woo JG, Guerrero ML, Ruiz-Palacios GM, Peng Y-m, Herbers PM, Yao W, et al. Specific Infant Feeding Practices Do Not Consistently Explain Variation in Anthropometry at Age 1 Year in Urban United States, Mexico, and China Cohorts. J Nutr 2013;143(2):166-174.
1
2. Azizi F, Azadbakht L, Mirmiran P. Trends in overweight, obesity and central fat accumulation among Tehranian adults between 1998–1999 and 2001–2002: Tehran lipid and glucose study. Ann Nutr Metab 2005 Jan-Feb;49(1):3-8.
2
3. Vriz O, Lu H, Visentin P, Nicolosi L, Mos L, Palatini P. Gender differences in the relationship between left ventricular size and ambulatory blood pressure in borderline hypertension The HARVEST Study. Eur Heart J 1997;18(4):664-670.
3
4. Wee CC, Huskey KW, Ngo LH, Fowler-Brown A, Leveille SG, Mittlemen MA, et al. Obesity, Race, and Risk for Death or Functional Decline Among Medicare BeneficiariesA Cohort Study. Annals Inter Med 2011;154(10):645-655.
4
5. Noël PH, Copeland LA, Perrin RA, Lancaster AE, Pugh MJ, Wang CP, et al. VHA Corporate Data Warehouse height and weight data: opportunities and challenges for health services research. J Rehabil Res Dev 2010;47(8):739-750.
5
6. Vincent JB. Chromium (III) complexes. Drugs Future 2003;28:1079-1086.
6
7. Racek J, Sindberg C, Moesgaard S, Mainz J, Fabry J, Müller L, et al. Effect of chromium-enriched yeast on fasting plasma glucose, glycated haemoglobin and serum lipid levels in patients with type 2 diabetes mellitus treated with insulin. Biol Trace Element Res 2013;155(1):1-4.
7
8. Tian H, Guo X, Wang X, He Z, Sun R, Ge S, et al. Chromium picolinate supplementation for overweight or obese adults. Cochrane Database Syst Rev 2013 Nov 29;11:CD010063.
8
9. Kobla HV, Volpe SL. Chromium, exercise, and body composition. Crit Rev Food Sci Nutr 2000;40(4):291-308.
9
10. Abdollahi M, Farshchi A, Nikfar S, Seyedifar M. Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials. J Pharm Pharmaceutic Sci 2013;16(1):99-114.
10
11. Padmavathi IJ, Rao KR, Venu L, Ismail A, Raghunath M. Maternal dietary chromium restriction programs muscle development and function in the rat offspring. Experiment Biol Med 2010;235(3):349-355.
11
12. Tian H, Wang X, Guo X, He Z, Sun R, Ge S, et al. Chromium picolinate supplementation for overweight or obese people. Cochrane Database Syst Rev 2013 Nov 29;11:CD010063.
12
13. Inanç N, Uyanik F, Sahin H, Yaman H, Erdem O. Effects of chromium supplementation on body composition, leptin, ghrelin levels and selected biochemical parameters in obese women. Trace Elements & Electrolytes. 2006;23(2):128.
13
14. Kim C-W, Kim B-T, Park K-H, Kim K-M, Lee D-J, Yang S-W, et al. Effects of short-term chromium supplementation on insulin sensitivity and body composition in overweight children: randomized, double-blind, placebo-controlled study. J Nutr Biochem 2011;22(11):1030-1034.
14
15. Crawford V, Scheckenbach R, Preuss H. Effects of niacin‐bound chromium supplementation on body composition in overweight African‐American women. Diabetes Obes Metab 1999;1(6):331-337.
15
16. Edwards WW, Pringle DD, Palfrey TC, Anderson D. Effects of chromium picolinate supplementation on body composition in in-season division I intercollegiate female swimmers. Medicina Sportiva 2012;16(3):99-103.
16
17. Yazaki Y, Faridi Z, Ma Y, Ali A, Northrup V, Njike VY, et al. A pilot study of chromium picolinate for weight loss. J Alter Complement Med 2010;16(3):291-299.
17
ORIGINAL_ARTICLE
Assessment of hypomagnesaemia in patients on proton pump inhibitors
Background: Proton pump inhibitors (PPIs) are commonly used for treatment of many gastrointestinal disorders. They are effective and potent, so their use is getting more and more attraction. There are reports of some adverse effects for PPIs especially in long term consumption. One of potentially serious side effects of PPI is hypomagnesaemia which can be life threatening. This study was designed to evaluate the effect of PPI on serum level of magnesium.
Materials and Methods: A cohort study was done on two groups of patients: 50 patients who used 40 mg Omeprazole less than 3 months and 50 patients with more than 6 months of same drug. Serum levels of Mg, Ca, K and PTH were measured before and after treatment. Results were analyzed with SPSS ver.21 Kolmogorov-Smirnov, Chi square, Mann Whitney, and Wilcoxon.
Results: No significant decrease was found in magnesium level between two groups before and after treatment. Serum level of Calcium was significantly decreased in patients with PPI use of less than three months.
Conclusions: Hypomagnesaemia did not occur in short-term use of PPI.
https://mjms.mums.ac.ir/article_4519_b7b0e2efe52def501fd90f1cc33faeeb.pdf
2015-05-22
123
128
10.22038/mjms.2015.4519
Hypomagnesaemia
Proton pump inhibitors
Hypocalcemia
Ahmad
Khosravi Khorashad
1
Professor, Gastroenterology and Hepatology, Department of internal medicine, Mashhad University of medical sciences, Mashhad, Iran
AUTHOR
Hassan
Vosoughinia
h.vossoghinia@gmai.com
2
Associate professor, Gastroenterology and Hepatology, Department of internal medicine, Mashhad University of medical sciences, Mashhad, Iran
AUTHOR
Maryam
Naghavi
naghavim@mums.ac.ir
3
General practitioner, Mashhad, Iran
AUTHOR
Elham
Mokhtari Amirmajdi
mokhtarie@mums.ac.ir
4
Assistant professor, Nayshabour faculty of medical sciences, Nayshabour, Iran
AUTHOR
Mohammad Reza
Farzanehfar
farzanefarmr@mums.ac.ir
5
Assistant professor, Gastroenterology and Hepatology, Department of internal medicine, Mashhad University of medical sciences, Mashhad, Iran
AUTHOR
Maryam
Hami
hamim@mums.ac.ir
6
Associate professor, Nephrology, Department of internal medicine, Mashhad University of medical sciences, Mashhad, Iran
AUTHOR
Lida
Jarahi
jarahil@mums.ac.ir
7
Assistant Professor of Community Medicine, Addiction Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mohammad Reza
Sheykhian
sheykhianmr@mums.ac.ir
8
Gastroenterologist/ hepatologist, Hasheminezhad hospital, Mashhad, Iran
AUTHOR
Mitra
Ahadi
ahadim@mums.ac.ir
9
: Assistant professor, Gastroenterology and Hepatology, Department of internal medicine, Mashhad University of medical sciences, Mashhad, Iran
LEAD_AUTHOR
ORIGINAL_ARTICLE
The Effect of eight weeks combined training on some insulin resistance markers in middle-aged men
Introduction: Cardiovascular diseases associated with the metabolic syndrome are the major cause of mortality in all over the world. We evaluated the effect of eight weeks combined training on some insulin resistance markers in middle-aged men. Materials and Methods: In this semi experimental study, 24 sedentary healthy middle aged men (age: 63.45±2.15 years, BMI: 24.10±2.5 kg/m2) with convenience sampling method, participated in this study. They were randomly categorized into two groups of 12 individuals: experimental and control. In the trained group, the volunteers undertook 8 weeks by 3 days/week take part in combiand training. The aerobic program training included: 20 mins duration with 60-70% HRR per session and the resistance training program was performed with 70% 1RM. Before and after the 8 weeks combined training, blood samples were taken and the concentrations of leptin, glucose, insulin and insulin resistance concentrations were determined. Data are analyzed using repeated measure test. P less than 0.05 was considered statistically significant. Results: The levels of the leptin, insulin, glucose, insulin resistance and body fat percentage in experimental group were improved significantly(P<0.05), Changes in average of two groups in levels of leptin, glucose, insulin resistance, body fat percentage had a significant difference (P<0.05). Conclusion: Reduced leptin and insulin resistance level following combined exercises training might improve cardiovascular risk in middle-aged men.
https://mjms.mums.ac.ir/article_4521_55db0363a5777e42fb496a658858a47a.pdf
2015-05-22
129
136
10.22038/mjms.2015.4521
Combined exercises
Insulin resistance indicators
Inactive middle-aged men
Leptin
Seyyed Reza
Attarzadeh Hosseini
attarzadeh@um.ac.ir
1
Associate Professor in Sport Physiology, Faculty of Physical Education and Sports Sciences, Ferdowsi University of Mashhad, Mashhad, Iran
LEAD_AUTHOR
Ehsan
Mir
hasanmoghadam@yahoo.com
2
2- MS.c of sport physiology, Faculty of Physical Education and Sports Sciences, Ferdowsi University of Mashhad, Mashhad,Iran
AUTHOR
Keyvan
Hejazi
keyvanhejazi1986@gmail.com
3
3- PhD student of Physical Education and Sport Sciences, Ferdowsi University of Mashhad, Mashhad, Iran
AUTHOR
Mojtaba
Mir Sayeedi
yazadmanesh@yahoo.com
4
MS.c of sport physiology, Faculty of Physical Education and Sports Sciences, Islamic Azad University of Kalale, Golestan, Iran
AUTHOR
1. Hashimoto H, Kitagawa K, Hougaku H, Etani H, Hori M. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke 2004;35(7):1625-1630.
1
2. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14(3):173-194.
2
3. Romero-Corral A, Sierra-Johnson J, Lopez-Jimenez F, Thomas RJ, Singh P, Hoffmann M, et al. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population. Nat Clin Pract Cardiovasc Med 2008 Jul;5(7):418-425.
3
4. Heald AH, Anderson SG, Ivison F, Laing I, Gibson JM, Cruickshank K. C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups. Atherosclerosis 2003 Sep;170(1):79-86.
4
5. Bonakdaran S, Barazandeh Ahmadabadi F. Assessment of insulin resistance in idiopathic hirsutism in comparison with polycystic ovary syndrome (PCOS) patients and healthy individuals. Med J Mashhad Univ Med Sci 2014;56(6):340-346.
5
6. Ridker P, Genest J, Libby P. Risk factor for atherosclerotic disease. In: Braunwald E. Heart disease. 2nd ed. Saunders 2006.
6
7. Pyörälä M, Miettinen H, Laakso M, Pyörälä K. Hyperinsulinemia Predicts Coronary Heart Disease Risk in Healthy Middle-aged Men The 22-Year Follow-up Results of the Helsinki Policemen Study. Circulation 1998;98(5):398-404.
7
8. Pérusse L, Collier G, Gagnon J, Leon A, Rao D, Skinner J. Acute and chronic effects of exercise on leptin levels in humans. J Appl Physiol 1997;83(1):5-10.
8
9. Kraemer R, Durand R, Acevedo E, Johnson L, Synovitz L, Kraemer G. Effects of high-intensity exercise on leptin and testosterone concentrations in well-trained males. Endocrine 2003;21(3):261-265.
9
10. Hojjati Z, Rahmani Niya F, Rahnama N, Soltani B. Heart disease and exercise. Sport Sci 2008;6(11):65-77.
10
11. Bouassida A, Zalleg D, Bouassida S, Zaouali M, Feki Y, Zbidi A, et al. Leptin, its implication in physical exercises and training: A short review. J Sports Sci Med 2006;5:172-181.
11
12. Gray S, Baker G, Wright A, Fitzsimons C, Mutrie N, Nimmo M. The effect of a 12 week walking intervention on markers of insulin resistance and systemic inflammation. Prevent Med 2009;48(1):39-44.
12
13. Carrel AL, McVean JJ, Clark RR, Peterson SE, Eickhoff JC, Allen DB. School-based exercise improves fitness, body composition, insulin sensitivity, and markers of inflammation in non-obese children. J Pediatr Endocrinol Metab 2009 May;22(5):409-415.
13
14. Ackel-D'Elia C, Carnier J, Bueno CR, Jr., Campos RM, Sanches PL, Clemente AP, et al. Effects of different physical exercises on leptin concentration in obese adolescents. Int J Sports Med 2014 Feb;35(2):164-171.
14
15. Gina M. Moderate-intensity aerobic training program improves insulin sensitivity and inflammatory markers in a pilot study of morbidly obese minority teens. Pediatr Exercise Sci 2013;25(1):12-26.
15
16. Wan-Long Z. Effects of long-term forced exercise training on body mass, energy metabolism and serum leptin levels in Apodemus chevrieri (Mammalia: Rodentia: Muridae). Italian J Zoology 2013;80(3):373-379.
16
17. Rahmani Nia F, Hojjati Z, Rahnama N, Soltani B. Leptin, heart disease and exercise. World J Sport Sci 2009;2:13-20.
17
18. Shamsi A, Ebadi A. Risk Factors of Cardiovascular Diseases in Elderly People. Iranian J Crit Care Nurs 2011;3(4):187-92.
18
19. Salehiomran M, Jafari S. Association of admission insulin resistance index with early cardiac complications in non diabetic patients with acute coronary syndrome. J Babol Univ Med Sci 2009;10(6):62-66.
19
20. Maliqueo M, Perez-Bravo F, Calvillan M, Piwonka V, Castillo T, Petermann T. [Relationship between leptin and insulin sensitivity in patients with polycystic ovary syndrome]. Medicina clinica 1999;113(14):526-530.
20
21. Sâmpelean D, Hanescu B, Han A, Adam M, Casoinic F. The Prognosis of Glycoregulation Disturbances and Insulin Secretion in Alcoholic and C Virus Liver Cirrhosis. Rom J Intern Med 2009;47(4):387-392.
21
22. Noushabadi A, Abedi B. Effects of combination training on insulin resistance index and some inflammatory markers in inactive men. Horizon Med Sci 2012;18(3):95-105.
22
23. Ghadiri Bahram Abadi N, Marandi S, Mojtahedi H, Esfarjani F. Effects of Aerobic Exercise Intensity on Serum Leptin Levels in Obese/Overweight Women. J Isfahan Med Sch 2012;30(183):392-399.
23
24. Cambuli V, Musiu M, Incani M, Paderi M, Serpe R, Marras V. Assessment of Adiponectin and Leptin as Biomarkers of Positive Metabolic Outcomes after Lifestyle Intervention in Overweight and Obese Children. J Clin Endocrinol Metab. 2008;93(8):3051-3057.
24
25. Bijeh N, Hosseini SA, Hejazi K. The effect of aerobic exercise on serum C - reactive protein and leptin levels in untrained middle-aged women. Iran J Public Health 2012;41(9):36-41.
25
26. Boutcher S. High-intensity intermittent exercise and fat loss. Obes Res 2011;1(1):868305.
26
27. Maesta N, Nahas E, Nahas N, Orsatti F, Fernandes C, Traiman P. Effects of soy protein and resistance exercise on body composition and blood lipids in postmenopausal women. Maturitas 2007;56(4):350-358.
27
28. Bell L, Watts K, Siafarikas A. Exercise alone reduces insulin resistance in obese children independently of changes in body composition. J Clin Endocrinol Metab 2007;92:4230-4235.
28
29. Suh S, Jeong I, Kim M, Kim Y, Shin S, Kim S, et al. Effects of Resistance Training and Aerobic Exercise on Insulin Sensitivity in Overweight Korean Adolescents: A Controlled Randomized Trial. Diabetes Metab J 2011;35(4):418-426.
29
30. van der Heijden GJ1, Wang ZJ, Chu ZD, Sauer PJ, Haymond MW, Rodriguez LM, et al. A 12-Week Aerobic Exercise Program Reduces Hepatic Fat Accumulation and Insulin Resistance in Obese, Hispanic Adolescents. Obesity 2010;18(2):384-390.
30
31. Nassis G, Papantakou K, Skenderi K. Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls. Metabolism 2005;54(11):1472-1479.
31
32. Eriksson J, Taimela S, Eriksson K, Parviainen S, Peltonen J, Kujala U. Resistance training the treatment of non-insulin-dependent diabetes mellitus. Int JSports Med 1997;18(4):242-246.
32
33. Das UN. Metabolic Syndrome Pathophysiology: The Role of Essential Fatty Acids. 1t ed. John Wiley & Sons; 2010.
33
ORIGINAL_ARTICLE
Comparison and evaluation of results of operative versus non operative treatment in one third fracture of clavicle
Background: Clavicle fractures are one of the most prevalent fractures. They are treated with surgery or conservative methods, but the best treatment is not clear. The aim of this study was comparison of operative with non operative treatments in the middle fracture of clavicle. Method: overall Sixty four patients aged between 20 to 65 years with middle clavicular fracture referring to Shahid Kamyab and Imam Reza Hospitals of Mashhad were recruited in 2013. Patients were randomly allocated to one of the two methods. Patients were followed for 6 months and demographic features, standard radiographic indices, DASH and VAS scores were recorded. Results: The rates of acceptable results were more in surgery group than in non surgery group (p=0.001). Surgical techniques for fractures of Midshaft of clavicula have many advantages versus non-surgical procedures and treatment is clinically and financially more affordable and better. Rate of complications was significantly lower in surgical procedure than non-surgical. In the surgical procedure period of hospitalization was longer (p=0.004) but time for returning to work and pain were less than nonsurgical method (p=0.004). Conclusion: In treatment of clavicular Midshaft fractures surgery was prior to non-surgery method and should be regarded as the treatment of choice
https://mjms.mums.ac.ir/article_4524_41a4f97d6e4a751451c6b26b9cfbf0da.pdf
2015-05-22
137
143
10.22038/mjms.2015.4524
comminuted fracture
malunion
nonunion
Farshid
Bagheri
bagherif@mums.ac.ir
1
Associate Professor of orthopedic shahid kamiab Hospital
AUTHOR
maryam
babazadeh
2
Resident of community medicine
AUTHOR
Syed rerza
shryfy
3
Associate Professor of Orthopedic
AUTHOR
Ali
Birjandinejad
birjandia@mums.ac.ir
4
Associate Professor of Orthopedic
AUTHOR
Mohammad Hossein
Jamshidi taraz
5
Associate Professor of Orthopedic
AUTHOR
Shahram
Athari niya
athariniyashahram@yahoo.com
6
Orthopedic Assistant in Mashhad University of Medical Sciences
LEAD_AUTHOR
McKee RC, Whelan DB, Schemitsch EH, McKee M. Operative versus nonoperative care of displaced midshaft clavicular fractures: a meta-analysis of randomized clinical trials. J Bone Joint Surg Am 2012 Apr 18;94(8):675-684.
1
Althausen PL, Shannon S, Lu M, O'Mara TJ, Bray TJ. Clinical and financial comparison of operative and no operative treatment of displaced clavicle fractures. J Shoulder Elbow Surg 2013 May;22(5):608-611.
2
Joo H.,Sae.H.,Jung Ha L.Treatment of distal cclavicle fracture:a systematic review of treatment modalities in 425 fractures. Arch Orthop Trauma Surg 2011 Apr;131(4):525-533.
3
Bonnevialle N, Delannis Y, Mansat P, Peter O, Chemama B, Bonnevialle P. Orthop Traumatol Surg Res 2010 Nov;96(7):821-824.
4
Oh JH, Kim SH, Lee JH, Shin SH, Gong HS. Treatment of distal clavicle fracture: a systematic review of treatment modalities in 425 fractures. Arch Orthop Trauma Surg 2011 Apr;131(4):525-533.
5
Mirzatolooei F. Comparison between operative and nonoperative treatment methods in the management of comminuted fractures of the clavicle. Acta Orthop Traumatol Turc 2011;45(1):34-40.
6
Lee YS, Lin CC, Huang CR, Chen CN, Liao WY. Operative treatment of midclavicular fractures in 62 elderly patients: knowles pin versus plate. Orthopedics 2007 Nov;30(11):959-964.
7
8
ORIGINAL_ARTICLE
Assessment of relationship between snoring and risk of coronary artery disease
Introduction: Snoring is common in the general population, with up to 25% of women and 45% of men reporting habitual snoring. Obstructive sleep apnea (OSA) is frequent and affects 4% and 2% of middle-aged men and women respectively. In some study, Snoring is associated with a significantly increased risk for acute myocardial infarction and stroke in men and women. Epidemiologic studies in Caucasian populations have shown association of snoring and sleep apnea with vascular disease. We examined whether snoring was directly related to cardiovascular disease. Methods: This article was case-control study. All patients underwent cardiac vessel angiography in two catheter labs in Qom hospitals. 92 patients were normal or minimal stenosis (<50%) and another 92 patients were with 1, 2 or 3 vessels disease. Then Berlin questionnairewas completeed by and compare two groups and analyzed using and the P Value less than (‹0.05)was consideredstatistically significant. SPSS16 software. Results: mean ageof patients was 55.83± 10.83,and 64.1% 118 (64.1%) patients were females. This study showed no significant difference between snoring with coronary artery disease (P=0.349). In the other hand, there are significant relationship between snoring and hypertension (P<0.001) and between risk factor of obstructive sleep apnea and coronary artery disease (P=0.008). However, we didn't show prominent relationship between snoring and diabetes mellitus also between snoring also hyperlipidemia (P=0.853, P=0.214 respectively) Conclusion: according to this study, in spite to correlation among risk factors of obstructive sleep apnea and coronary artery disease, simple snoring was not risk factor for development of cardiovascular disease.
https://mjms.mums.ac.ir/article_4526_ccea6788b96615bc77f5029187c6d8b1.pdf
2015-05-22
144
150
10.22038/mjms.2015.4526
Coronary Artery Disease
Snoring
Obstructive Sleep Apnea
Abolfazl
Mozafari
a_mozafari@hotmail.com
1
Associated professor, Department of Medical Sciences, Qom Branch, Islamic Azad University, Qom, Iran
LEAD_AUTHOR
Seid Fakhredin
Hejazi
2
Associated professor, Department of Medical Sciences, Qom University Medical Sciences, Qom, Iran
AUTHOR
Zahra
Afrakhteh
3
General physician, Department of Medical Sciences, Qom Branch, Islamic Azad University, Qom, Iran
AUTHOR
- Fazeleh
Shakeri
4
General physician, Department of Medical Sciences, Qom Branch, Islamic Azad University, Qom, Iran
AUTHOR
Siamak
Mohebi
5
- Associated professor, Department of Public Health, School of Health, Qom University Medical Sciences, Qom, Iran
AUTHOR
Hadi
Zamanian
6
Associated professor, Department of Public Health, School of Health, Tehran University of medical sciences, Tehran, Iran
AUTHOR
. Liistro G, Stanescu DC, Veriter C, Rodenstein DO, Aubert-Tulkens G. Pattern of snoring in obstructive sleep apnea patients and in heavy snorers. Sleep 1991;14(6):517-525.
1
2. Cirignotta F. Classification and definition of respiratory disorders during sleep. Minerva Med 2004;95(3):177-185.
2
3. Zintzaras E, Kaditis AG. Sleep-disordered breathing and blood pressure in children: a meta-analysis. Arch Pediatr Adolesc Med 2007 Feb;161(2):172-178.
3
4. Hiestand DM, Britz P, Goldman M, Phillips B. Prevalence of symptoms and risk of sleep apnea in the US population - Results from the National Sleep Foundation Sleep in America 2005 Poll. Chest 2006;130(3):780-786.
4
5. Dunai A, Keszei AP, Kopp MS, Shapiro CM, Mucsi I, Novak M. Cardiovascular Disease and Health-Care Utilization in Snorers: a Population Survey. Sleep 2008 Mar;31(3):411-416.
5
6. Adewole OO, Adeyemo H, Ayeni F, Anteyi EA, Ajuwon ZO, Erhabor GE, et al. Prevalence and correlates of snoring among adults in Nigeria. African health Sci 2008 Jun;8(2):108-113.
6
7. Pin Arboledas G, Rosello AL, Alarco MC, Safort MM. [Epidemiology. Risk factors and genetic influence]. Acta Otorrinolaringol Esp 2010 Dec;61 Suppl 1:7-13.
7
8. Leineweber C, Kecklund G, Janszky I, Akerstedt T, Orth-Gomer K. Snoring and progression of coronary artery disease: The Stockholm Female Coronary Angiography Study. Sleep 2004 Nov 1;27(7):1344-1349.
8
9. Hu FB, Willett WC, Manson JE, Colditz GA, Rimm EB, Speizer FE, et al. Snoring and risk of cardiovascular disease in women. J Am Coll Cardiol 2000;35(2):308-313.
9
10. Bounhoure JP, Galinier M, Didier A, Leophonte P. [Sleep apnea syndromes and cardiovascular disease]. Bull Acad Natl Med 2005 Mar;189(3):445-459; discussion 60-4.
10
11. Chen JC, Brunner RL, Ren H, Wassertheil-Smoller S, Larson JC, Levine DW, et al. Sleep duration and risk of ischemic stroke in postmenopausal women. Stroke 2008 Dec;39(12):3185-3192.
11
12.Lavie P, Lavie L, Herer P. All-cause mortality in males with sleep apnoea syndrome: declining mortality rates with age. Eur Respir J 2005;25(3):514-520.
12
13. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med1999; 131(7):485-491.
13
14. American Diabetes Association: Clinical Practice Guidelines 2003. Diabetes Care 2003;26(Suppl. 1):S12.
14
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-2497
15
16. Punjabi NM. The Epidemiology of Adult Obstructive Sleep Apnea. Proc Am Thorac Soc 2008;5(2):136-143.
16
17. Gami AS, Olson EJ, Shen WK, Wright RS, Ballman KV, Hodge DO, et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coll Cardiol 2013 Aug 13;62(7):610-616.
17
18. Koehler U, Apelt S, Augsten M, Dette F, Jerrentrup L, Langanke J, et al. [Daytime sleepiness in patients with Obstructive Sleep Apnoea (OSA) - pathogenetic factors]. Pneumologie (Stuttgart, Germany) 2011 Mar;65(3):137-142.
18
19. Jennum P, Hein HE, Suadicani P, Gyntelberg F. Risk of ischemic heart disease in self reported snorers: A prospective study of 2,937 men aged 54 to 74 years: the Copenhagen male study. Chest 2005; 108(1):138-142.
19
20 Mosca M, Aggarwal B. Sleep duration, snoring habits, and cardiovascular disease risk factors in an ethnically diverse population. Journal Cardiovas Nurs 2012 May-Jun;27(3):263-269.
20
21. Lee SA, Amis TC, Byth K, Larcos G, Kairaitis K, Robinson TD. Heavy Snoring as a Cause of Carotid Artery Atherosclerosis. Sleep 2008 Sep;31(9):1207-1213.
21
22. Dunai A, Keszei AP, Kopp MS, Shapiro CM, Mucsi I, Novak M. Cardiovascular disease and health-care utilization in snorers: a population survey. Sleep 2008 Mar;31(3):411-416.
22
23. Weitzenblum E, Chaouat A. Obstructive sleep apnea syndrome and the pulmonary circulation. Ital Heart J 2005 Oct;6(10):795-798.
23
24. Bednarek M, Polakowska M, Kurjata P, Kupść W, Plywaczewski R. Snoring and excessive daytime somnolence and risk of cardiovascular diseases. Pol Arch Med Wewn 2001 Jan;105(1):11-17.
24
ORIGINAL_ARTICLE
The prevalence of HGV serologic markers in hemodialysis and hemophilia patients in Mashhad
Background: hepatitis G virus (HGV) is an RNA virus. The predominant route of its transmission is parenteral. The aim of this study was to assess the frequency of HGV exposure in hemodialysis (HD) and hemophiliac patients in Mashhad. Methods: this cross-sectional study was performed in Ghaem hospital, although we selected our hemodialysis patients from 4 major dialysis centers in Mashhad (Imam reza hospital, Hasheminejad hospital, Ghaem hospital and Emam zaman hospital). We asked hemophilic patients to participate our study from all around Khorasan (Razavi, North and South). The study consisted of 132 patients under HD and 101 hemophilic patients. The presence of anti-HGV envelope protein E2 (anti-E2) in blood serum was determined by means of an ELISA assay that indicates HGV exposure. All patients were also screened for hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV), alanine aminotransferase (ALT), aspartat aminotransferase (AST) and alkaline phosphatase (ALP). Data of the study was inserted in SPSSand was analyzed with the chi-square and T test. Results: totally, none of the HD or hemophilic patients are positive for anti-E2. 84.1% of hemodialysis patients and all of the hemophiliac patients had previous blood transfusion . Conclusion: the rate of exposure to HGV was zero (0%) among the dialysis and hemophiliac patients in our study. therefore it seemd that screening for HGV Ab was not necessary in Mashhad.
https://mjms.mums.ac.ir/article_4528_e1a71ec86070e9a96f6598fef9d0dcb7.pdf
2015-05-22
151
155
10.22038/mjms.2015.4528
anti-HGV envelope protein E2
hemophiliac
hemodialysis
hepatitis G virus
Mohammad javad
Mojahedi
mojahedimj@mums.ac.ir
1
professor of Nephrology .Department of nephrology , Mashhad university of medical science ,Mashhad IR Iran
AUTHOR
Samane
Esfandiari
esfandiaris911@mums.ac.ir
2
Assistant of occupational medicine , Department of occupational medicine , Mashhad university of medical science ,Mashhad IR Iran
AUTHOR
Ali
Pourakbar
ali_pourakbar@yahoo.com
3
Gastroenterology Fellow ,Department of Gastroenterology and Hepatology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran.
LEAD_AUTHOR
Maryam
Hami
hamim@mums.ac.ir
4
Associate Professor, Department of Nephrology , Mashhad university of medical science ,Mashhad IR Iran
AUTHOR
Hushang
Rafatpanah
rafatpanahh@mums.ac.ir
5
Associate Professor of immunology, Immunology Research Center, Mashhad University of Medical Sciences, Mashhad IR Iran
AUTHOR
1.Fabrizi F, Raffaele L, Bacchini G, Guarnori I, Pontoriero G, Erba G, et al. Antibodies to hepatitis C virus (HCV) and transaminase concentration in chronic haemodialysis patients: a study with second-generation assays. Nephrol Dialysis Transplant 1993;8(8):744-747.
1
2.Simons JN, Pilot-Matias TJ, Leary TP, Dawson GJ, Desai SM, Schlauder GG, et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci U S A 1995;92(8):3401-3405.
2
3.Linnen J, Wages J, Zhang-Keck Z-Y, Fry KE, Krawczynski KZ, Alter H, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271(5248):505-508.
3
4.Schlauder GG, Dawson GJ, Simons JN, Pilot‐Matias TJ, Gutierrez RA, Heynen CA, et al. Molecular and serologic analysis in the transmission of the GB hepatitis agents. Journal of medical virology. 1995;46(1):81-90.
4
5.Kleinman S. Hepatitis G virus biology, epidemiology, and clinical manifestations: implications for blood safety. Transfus Med Rev 2001;15(3):201-212.
5
6.Dille BJ, Surowy TK, Gutierrez RA, Coleman PF, Knigge MF, Carrick RJ, et al. An ELISA for detection of antibodies to the E2 protein of GB virus C. J Infect Dis 1997;175(2):458-461.
6
7.Hwang SJ, Chu CW, Lu RH, Lan KH, Wu JC, Wang YJ, et al. Seroprevalence of GB virus C/hepatitis G virus–RNA and anti‐envelope antibody in high‐risk populations in Taiwan. J Gastroenterol Hepatol 2000;15(10):1171-1175.
7
8.Daw MA, Dau AA. Hepatitis C virus in Arab world: a state of concern. ScientificWorldJournal. 2012;2012:719494.
8
9.Fallahian F, Najafi A. Epidemiology of hepatitis C in the Middle East. Saudi J Kidney Dis Transpl 2011 Jan;22(1):1-9.
9
10.Leary TP, Muerhoff S, Simons JN, Pilot‐Matias TJ, Erker JC, Chalmers ML, et al. Sequence and genomic organization of GBV‐C: A novel member of the flaviviridae associated with human non‐A‐E hepatitis. J Med Virol 1996;48(1):60-67.
10
11.Kafi-Abad SA, Samiei S, Talebian A, Maghsudloo A, Gharehbaghian A. Hepatitis G virus infection in Iranian blood donors and high-risk groups. Hepatitis Monthly 2009;9(4):282-286.
11
12.Eslamifar A, Hamkar R, Ramezani A, Ahmadi F, Gachkar L, Jalilvand S, et al. Hepatitis G virus exposure in dialysis patients. Int Urol Nephrol 2007;39(4):1257-1263.
12
13.Cornu C, Jadoul M, Loute G, Goubau P. Hepatitis G virus infection in haemodialysed patients: epidemiology and clinical relevance. Nephrol Dialysis Transplant 1997 July 1;12(7):1326-1329.
13
14.de Lamballerie X, Charrel R, Dussol B. Hepatitis GB virus C in patients on hemodialysis. N Engl J Med 1996;334(23):1549.
14
15.Bastani B, Frenche D, Gellens M, Di Bisceglie A. Infection with hepatitis G (HGV) and hepatitis C (HCV) viruses in patients on chronic hemodialysis. Am J Nephrol 1998;9:199A.
15
16.Ross R, Viazov S, Schmitt U, Schmolke S, Tacke M, Ofenloch‐Haehnle B, et al. Distinct prevalence of antibodies to the E2 protein of GB virus C/hepatitis G virus in different parts of the world. J Med Virol 1998;54(2):103-106.
16
17.Eslamifar A, Hamkar R, Ramezani A, Ahmadi F, Gachkar L, Jalilvand S, et al. Hepatitis G virus exposure in dialysis staff. Ther Apher Dial 2007 Oct;11(5):370-374.
17
18.Kupfer B, Ruf T, Matz B, Nattermann J, Spengler U, Rockstroh JK, et al. Comparison of GB virus C, HIV, and HCV infection markers in hemophiliacs exposed to non-inactivated or inactivated factor concentrates. J Clin Virol 2005;34(1):42-47.
18
19.Fallahian F, Alavian SM, Rasoulinejad M. Epidemiology and transmission of hepatitis G virus infection in dialysis patients. Saudi J Kidney Dis Transpl 2010 Sep;21(5):831-834.
19
20.Chopra S, Adrian M, Grover S. GB virus C (hepatitis G) infection. Up to Date. Mar 2015.
20
ORIGINAL_ARTICLE
Association of C3 gene polymorphism with age related macular degeneration in Gonabad region from NorthEast of Iran
Introduction Age-related macular degeneration (AMD) is the most common cause of irreversible visual impairment among elderly population worldwide. Besides age and smoking, genetic variants from several gene loci have been associated with this condition. Several polymorphisms have been implicated in the pathogenesis of this disease. rs2230199 polymorphism in C3 gene that encodes the major protein of the complement system is one of the candidate genes involved in this disease. The present research examined the role of R102G polymorphism in developing of AMD. Method In this study, the association of rs2230199 polymorphism in C3 gene was investigated in 51 patients from Gonabad region suffering from dry AMD with Geogrophic atrophy by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Some cases were chosen at random for confirmation of the PCR-RFLP results by direct sequencing. Also, 72 healthy age, sex matched unrelated people were included in this case-control study as controls which were selected from the same population. Results Investigation of the association of R102G polymorphism in C3 gene with AMD showed that there are significant differences between patients and controls in genotype and allele frequencies of this polymorphism (P= 0.000) . Conclusion rs2230199 polymorphism in C3 was associated with increased risk for AMD
https://mjms.mums.ac.ir/article_4535_a3839a10139be93ca47c8cfd59ed0515.pdf
2015-05-22
156
161
10.22038/mjms.2015.4535
AMD
C3 gene
RFLP
Mortaza
Bonyadi
jabbarpour@tabrizu.ac.ir
1
Associate Professor in Molecular Medical Genetics- Animal Biology Dept. Faculty of Natural Sciences, University of Tabriz.Tabriz
LEAD_AUTHOR
Sanaz
Ranjbar Rad
s.rnj1987@yahoo.com
2
MSc in Genetics, Biology Dept. Faculty of Natural Sciences, Islamic Azad University of Ahar. Ahar
AUTHOR
Mohammad Hossein
Jabbarpour Bonyadi
mhbonyadi@yahoo.com
3
MD in Ophthalmology, Ophthalmologist, Eye Section, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad.
AUTHOR
Hamid
Ahmadieh
labbafi@hotmail.com
4
Professor in Retina. Ophthalmic Research Center, Shahid Beheshty University of Medical Sciences. Tehran
AUTHOR
1. Holliday EG, Smith AV, Cornes BK, Buitendijk GH, Jensen RA, Sim X, et al. Insights into the Genetic Architecture of Early Stage Age-Related Macular Degeneration: A Genome-Wide Association Study Meta-Analysis. PLoS One 2013;8(1):e52830.
1
2. Parmeggiani F, Sorrentino FS, Romano MR, Costagliola C, Semeraro F, Incorvaia C, et al. Mechanism of Inflammation in Age-Related Macular Degeneration: An Up-to-Date on Genetic Landmarks. Mediators Inflamm 2013;2013:435607.
2
3. Age-Related Eye Disease Study Research Group. Risk Factors Associated with Age-Related Macular Degeneration: A Case-control Study in the Age-Related Eye Disease Study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000;107(12):2224-2232.
3
4. Guymer RH, Chong EW. Modifiable Risk Factors of Age-Related Macular Degeneration. Med J Aust 2006 May 1;184(9):455-458.
4
5. Scholl H, Fleckenstein M, Issa P,Keilhauer C, Holz F, Weber BH. An update on the genetics of age-related macular degeneration. Mol Vis 2007;13:196-205.
5
6. Thakkinstian A, McKay GJ, McEvoy M, ChakravarthyU, Chakrabarti S, Silvestri G, et al. Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol 2011;173(12):1365-1379.
6
7. Gregory S. Hageman PJL, N.H. Victor Chong, Lincoln V. Johnsonc,Don H. Andersonc, Robert F. Mullins. An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch's Membrane Interface in Aging and Age-Related Macular Degeneration. Am J Epidemiol 2001;173(12):1365-1379.
7
8. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006;58(3):353-363.
8
9. Ratnapriya R CE. Age-related macular degeneration – clinical reviewand genetics update. Clin Genet. 2013;84(2):160-6.
9
10. Bressler NM. Early Detection and Treatment of Neovascular Age-related Macular Degeneration. J Am Board Fam Pract 2002;15(2):142-152.
10
11. Katta S, Kaur I, Chackrabarti S. The molecular genetic basis of age-related macular degeneration: an overview. J Genet 2009;88(4):425-449.
11
12. van de Ven JP, Smailhodzic D, Boon CJ, Fauser S, Groenewoud JM, Chong NV, et al. Association analysis of genetic and environmental risk factors in the cuticular drusen subtype of age-related macular degeneration. Mol Vis 2012;18:2271-2278.
12
13. Swaroop A, Branham KE, Chen W, Abecasis G. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum Mol Genet 2007;16(2):174-182.
13
14. Leveziel N, Puche N, Zerbib J, Benlian P, Coscas G, Soubrane G, Souied E. Genetic Factors Associated with Age-Related Macular Degeneration. Med Sci (Paris) 2010;26(5):509-515.
14
15. Gorin MB. Genetic insights into age-related macular degeneration: Controversies addressing Risk, Causality, and Therapeutics. Mol Aspects Med 2012;33(4):467-486.
15
16. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement Factor H Polymorphism in Age-Related Macular Degeneration. Science 2005;308(5270):384-389.
16
17. Thakkinstian A, McEvoy M, Chakravarthy U, Chakrabarti S, McKay GJ, Ryu E, et al. The Association Between Complement Component 2/Complement Factor B Polymorphisms and Age-related Macular Degeneration: A HuGE Review and Meta-Analysis. Am J Epidemiol 2012;176(5):361-372.
17
18. Francis PJ, Hamon SC, Ott J, Weleber RG, Klein ML. Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. J Med Genet 2009;46(5):300-307.
18
19. Zipfel PF, Lauer N, Skerka C. The Role of Complement in AMD. Adv Exp MedBiol 2010;703:9-24.
19
20. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM. Plasma Complement Components and Activation Fragments: Associations with Age-Related Macular Degeneration Genotypes and Phenotypes. Invest Ophthalmol Vis Sci 2009;50(12): 5818-5827.
20
21. Botto M, Fong Ky, So AK, Koch C, Walport MJ. Molecular Basis of Polymorphisms of Human Complement Component C3. J Exp Med 1990;172(4):1011–1017.
21
22. Park KH FB, Ryu E, Tosakulwong N, Edwards AO. Complement Component 3 (C3) Haplotypes and Risk of Advanced Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 2009;50(7):3386-3393.
22
23. Yates J, SeppT, Matharu BK, Khan JC, Thurlby D, Shahid H, et al. Complement C3 Variant and the Risk of Age-Related Macular Degeneration. N Engl J Med 2007;357(6):553-561.
23
24. Spencer KL, Olson LM, Anderson BM, Schnetz-Boutaud N, Scott WK, Gallins P, et al. C3 R102G polymorphism increases risk of age-related macular degeneration. Hum Mol Genet 2008;17(12):1821-1824.
24
25. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39(5):367-374.
25
26. Miller SA, Dykes D, Polsky F. A simple salting out procedure for extracting DNA from human nucleatedcells. Nucleic Acids Res 1988;16(3):1215.
26
27. Buentello-Volante B R-RG, Miranda-Duarte A, Pompa-Mera EN, Graue-Wiechers F, Bekker-Méndez C. Susceptibility to advanced age-related macular degeneration and alleles of complement factor H, complement factor B, complement component 2, complement component 3, and age-related maculopathy susceptibility 2 genes in a Mexican population. Mol Vis 2012;15:2518-2525.
27
28. Zerbib J, Richard F, Puche N, Leveziel N, Cohen SY, Korobelnik JF, et al. R102G polymorphism of the C3 gene associated with exudative age-related macular degeneration in a French population. Mol Vis 2010;16:1324-1330.
28
29. McKay GJ DS, Patterson CC, Chakravarthy U, Silvestri G. Complement Component 3: an assessment of association with AMD and analysis of gene-gene and gene-environment interactions in a Northern Irish cohort. Mol Vis 2010;16:194-199.
29
30. Cui L ZH, Yu J, Sun E, Zhang Y, Jia W, et al. Noncoding Variant in the Complement Factor H Gene and Risk of Exudative Age-Related MacularDegeneration in a Chinese Population. Invest Ophthalmol Vis Sci 2009;51(2):1116-1120.
30
31. Yanagisawa S, Kondo N, Miki A, Matsumiya W, Kusuhara S, Tsukahara Y, et al. A Common Complement C3 Variant Is Associated with Protection against Wet Age-Related Macular Degeneration in a Japanese Population. PLoS One 2011;6(12):e28847.
31
32. Kim SJ, Lee SJ, Kim NR, Chin HS. Association of polymorphisms in C2, CFB and C3 with exudative age-related macular degeneration in a Korean population. Exp Eye Res 2012;96(1): 42-47.
32
ORIGINAL_ARTICLE
Evaluation of the relationship between 25-hydroxy Vit D (25 OH Vit D) and hemoglobin, and erythropoietin index (EPOI) in hemodialysis
Introduction: Recent studies have shown that vitamine D stimulates erythropoiesis,. The aim of this study was to evaluate relation of 25 hydroxy Vit D (25 OH Vit D) with hemoglobin and erythropoietin Index (EPOI) in hemodialysis patients . Materials & Methods: Our study enrolled 62 HD patients treated at Imam Reza Hospital in year 2012. The patients included 36 men and 26women, in this cross sectional study. Blood samples were obtained for determination of 25 OH Vit D, hemoglobin and EPOI computed (weekly EPO dose/hematocrit) .We considered resistance to EPO as EPOI > 300. Pearson’s correlation coefficient method was used for specifying the correlation between variable levels. Results: The mean age of patients was 42.26±13.28 years. The mean Vit D levels were 26.54 ± 20.28. Overall Twenty four patients (38.7%) had resistance to erythropoietin. In this study we didn`t find any correlation between 25 OH Vit D and hemoglobin and EPOI. In patients with EPOI > 300, there was an inverse significant correlation between 25 OH Vit D and EPOI (r=-0.42, p=0.04). Conclusion: In spite of absence of relationship between EPOI and 25 OH Vit D levels in our study, in HD patients who showed resistance to erythropoietin, it might be an inverse significant correlation between 25 OH Vit D and EPOI, that should be approved in further studies.
https://mjms.mums.ac.ir/article_4537_e9e04411b1f22401bbf26c2d3f745e01.pdf
2015-05-22
162
166
10.22038/mjms.2015.4537
Vitamin D
Hemoglobin
Erythropoietin Index
hemodialysis
Abbasali
Zeraati
zeraaty@mums.ac.ir
1
associate professor of nephrology , Kidney Transplantation Complications research center, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Parvin
Layegh
layeghpa@mums.ac.ir
2
, assistant professor of endocrinology & metabolism, Endocrine Research Center, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
-Masumeh
hasan zadeh
hasanzadehm891@mums.ac.ir
3
resident of Internal Medicine, Kidney Transplantation Complications research center, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Farzaneh Sharifipour
Sharifipour
sharifipourfa@mums.ac.ir
4
associate professor of nephrology, Kidney Transplantation Complications research center , Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Seyyed Seifollah
Beladi Mousavi
5
Associate Professor, Chronic Renal Failure Research Center, Department of Internal Medicine, Faculty of Medicine, Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Andisheh
noruzian
6
student of Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Tina
Zeraati
tina@mums.ac.ir
7
Medical Student, Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
1.Lameire NH, Eknoyan G. Clinical practice guidelines for anemia in chronic kidney disease:problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2008 Nov;74(10):1237-1240.
1
2. Gillespie BS, Inrig JK, Szczech LA. Anemia management in chronic kidney disease. Hemodial Int 2007 Jan;11(1):15-20.
2
3. Bárány P, Müller HJ. Maintaining control over haemoglobin levels: ptimizing
3
the management of anaemia in chronic kidney disease. Nephrol Dial Transplant 2007 Jun;22(Suppl 4):iv10-iv18.
4
4.Kimata N, Akiba T, Pisoni RL, Albert JM, Satayathum S, Cruz JM, et al. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2005 May;20(5):927-935.
5
5. Patel NM, Gutiérrez OM, Andress DL, Coyne DW, Levin A, Wolf M. Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 2010 Apr;77(8):715-720.
6
6. Nazem AK, Makó J. The effect of calcitriol on renal anaemia in patients undergoing long-term dialysis. Int Urol Nephrol 1997;29(1):119-127.
7
7. Kiss Z, Ambrus C, Almasi C, Berta K, Deak G, Horonyi P, et al. Serum 25(OH)-cholecalciferolconcentration is associated with hemoglobin level and erythropoietin resistancein patients on maintenance hemodialysis. Nephron Clin Pract 2011;117(4):c373-378.
8
8.Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreño V, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998 Oct;54(4):1337-1343.
9
9. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, et al. European Best PracticeGuidelines Working Group. Revised European best practiceguidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004 May;19 Suppl 2:ii1-47.
10
10. Hörl WH, Jacobs C, Macdougall IC, Valderrábano F, Parrondo I, Thompson K, et al. European bestpractice guidelines 14–16: inadequate response to epoetin. Nephrol Dial Transplant 2000;15 Suppl 4:43-50.
11
11. Greenwood RN, Ronco C, Gastaldon F, Brendolan A, Homel P, Usvyat L, et al. Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance. Kidney Int Suppl 2003 Nov;(87):S78-86.
12
12. Goicoechea M, Vazquez MI, Ruiz MA, Gomez-Campdera F, Perez-García R, Valderrábano F. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. Nephron 1998;78(1):23-27.
13
13.Neves PL, Triviño J, Casaubon F, Santos V, Mendes P, Romão P, et al. Elderly patients on chronic hemodialysis with hyperparathyroidism: increase of hemoglobin level after intravenous calcitriol. Int Urol Nephrol 2006;38(1):175-177.
14
14. Perlstein TS, Pande R, Berliner N, Vanasse GJ. Prevalence of 25-hydroxyvitaminD deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood 2011 Mar 10;117(10):2800-2806.
15
15. Zittermann A, Jungvogel A, Prokop S, Kuhn J, Dreier J, Fuchs U, et al. Vitamin D deficiency is an independent predictor of anemia in end-stage heart failure. Clin Res Cardiol 2011 Sep;100(9):781-788.
16